Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 8.26%74.69M | 631.49%25.57M | -66.13%7.74M | -42.64%13.7M | 47.59%27.68M | 21.86%68.99M | -78.63%3.5M | 4.38%22.86M | 327.56%23.89M | 46.85%18.75M |
Net income from continuing operations | 1.86%43.29M | 32.28%12.31M | 18.77%10.32M | -15.76%10.68M | -15.60%9.99M | -8.16%42.5M | -15.46%9.3M | -33.49%8.69M | 15.74%12.68M | 5.10%11.84M |
Operating gains losses | -130.86%-75K | -159.09%-130K | 61.96%-334K | 21.18%206K | -74.97%183K | -93.51%243K | -90.91%220K | -162.87%-878K | -87.35%170K | 129.87%731K |
Depreciation and amortization | 1.31%20.82M | 6.19%5.45M | -4.31%5.26M | 7.24%5.22M | -3.23%4.89M | 3.83%20.55M | 3.97%5.14M | 21.65%5.5M | -10.14%4.87M | 2.68%5.05M |
Deferred tax | 51.70%-1.56M | 146.74%401K | -230.08%-406K | 77.69%-805K | -155.81%-754K | 17.06%-3.24M | 33.02%-858K | 91.58%-123K | -546.59%-3.61M | 323.31%1.35M |
Other non cash items | 68.29%-1.6M | 87.09%-916K | -74.50%407K | -170.50%-270K | -1,177.63%-819K | 10.10%-5.04M | -12,123.73%-7.09M | 326.06%1.6M | 109.62%383K | 107.78%76K |
Change In working capital | 18.95%12.24M | 261.06%8.15M | -202.16%-7.58M | -121.91%-1.94M | 1,588.51%13.61M | 275.79%10.29M | -96.47%-5.06M | 10.93%7.42M | 211.29%8.84M | 54.82%-914K |
-Change in receivables | -265.12%-9.33M | 96.80%-559K | -147.71%-6.8M | -133.30%-4.35M | 157.10%2.38M | 203.14%5.65M | -659.57%-17.49M | 284.02%14.25M | 1,978.50%13.05M | 44.62%-4.16M |
-Change in payables and accrued expense | 1,526.57%13.96M | -31.78%6.87M | 135.68%1.36M | 352.43%3.01M | 164.62%2.72M | 517.27%858K | 746.34%10.06M | -174.44%-3.8M | 78.12%-1.19M | -502.43%-4.21M |
-Change in other working capital | 101.35%7.61M | -22.31%1.84M | 29.50%-2.14M | 79.99%-604K | 14.08%8.51M | 836.65%3.78M | 262.29%2.37M | -42.50%-3.03M | 3.08%-3.02M | 20.48%7.46M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 8.26%74.69M | 631.49%25.57M | -66.13%7.74M | -42.64%13.7M | 47.59%27.68M | 21.86%68.99M | -78.63%3.5M | 4.38%22.86M | 327.56%23.89M | 46.85%18.75M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 18.86%-22.41M | -110.48%-494K | -305.04%-3.69M | 15.98%-16.96M | 88.74%-1.27M | 19.86%-27.62M | 288.30%4.72M | 93.29%-912K | -125.90%-20.18M | -19.10%-11.24M |
Capital expenditure reported | 16.75%-2.65M | 47.39%-443K | 20.18%-724K | -1.66%-735K | -5.20%-748K | -4.05%-3.18M | -15.34%-842K | -25.28%-907K | 1.50%-723K | 18.37%-711K |
Net PPE purchase and sale | 4.73%-1.49M | 28.88%-532K | -69.15%-340K | -91.85%-353K | 38.52%-265K | 64.30%-1.56M | 30.61%-748K | 81.68%-201K | 90.34%-184K | -42.72%-431K |
Net intangibles purchase and sale | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net business purchase and sale | 27.43%-19.34M | -99.05%61K | -1,296.88%-1.79M | 23.74%-17.36M | 97.55%-249K | -0.40%-26.65M | 427.02%6.4M | 98.82%-128K | -489.13%-22.76M | 22.16%-10.15M |
Net investment purchase and sale | -62.78%1.07M | 351.50%420K | -2,906.67%-842K | -49.42%1.49M | -105.56%-3K | 44.00%2.87M | -149.12%-167K | 103.28%30K | 222.76%2.95M | -98.91%54K |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | 140.40%909K | --74K | --294K | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 18.86%-22.41M | -110.48%-494K | -305.04%-3.69M | 15.98%-16.96M | 88.74%-1.27M | 19.86%-27.62M | 288.30%4.72M | 93.29%-912K | -125.90%-20.18M | -19.10%-11.24M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -161.06%-45.15M | -9.84%-11.41M | 30.66%-14.12M | -22,070.31%-14.19M | -140.15%-5.43M | 5.38%-17.29M | 0.78%-10.39M | -42.76%-20.36M | 99.54%-64K | -33.42%13.52M |
Net issuance payments of debt | -219.05%-27.12M | 15.84%-8.51M | 56.76%-1.34M | -167.95%-14.24M | -120.12%-3.03M | 96.59%22.78M | -9.66%-10.11M | -287.23%-3.11M | 832.69%20.96M | -31.64%15.05M |
Cash dividends paid | 67.48%-10.02M | --0 | 37.63%-10.02M | ---- | ---- | -23.98%-30.8M | --0 | -12.80%-16.06M | ---- | ---- |
Proceeds from stock option exercised by employees | --0 | ---- | ---- | ---- | ---- | 2,100.00%22K | ---- | ---- | ---- | ---- |
Net other financing activities | 13.87%-8.01M | -867.33%-2.9M | -131.21%-2.76M | 100.80%50K | -57.27%-2.4M | -85.07%-9.3M | 76.04%-300K | 29.22%-1.19M | -1,535.42%-6.28M | 10.45%-1.53M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -161.06%-45.15M | -9.84%-11.41M | 30.66%-14.12M | -22,070.31%-14.19M | -140.15%-5.43M | 5.38%-17.29M | 0.78%-10.39M | -42.76%-20.36M | 99.54%-64K | -33.42%13.52M |
Net cash flow | ||||||||||
Beginning cash position | 27.55%105.94M | -6.40%98.94M | 2.89%107.64M | 22.73%125.8M | 27.55%105.94M | -5.71%83.06M | 27.72%105.7M | 18.54%104.62M | -7.36%102.51M | -5.71%83.06M |
Current changes in cash | -70.36%7.14M | 727.26%13.67M | -735.73%-10.07M | -578.68%-17.44M | -0.24%20.98M | 520.54%24.08M | -164.35%-2.18M | 126.62%1.58M | 121.19%3.64M | -11.02%21.03M |
Effect of exchange rate changes | 74.79%-303K | -93.01%169K | 374.00%1.37M | 53.10%-718K | 29.31%-1.12M | 86.51%-1.2M | 178.39%2.42M | -208.93%-500K | 70.56%-1.53M | -47.09%-1.59M |
End cash Position | 6.45%112.78M | 6.45%112.78M | -6.40%98.94M | 2.89%107.64M | 22.73%125.8M | 27.55%105.94M | 27.55%105.94M | 27.72%105.7M | 18.54%104.62M | -7.36%102.51M |
Free cash flow | 9.84%70.51M | 1,211.73%24.6M | -69.47%6.64M | -45.02%12.63M | 51.32%26.65M | 31.12%64.19M | -87.12%1.88M | 8.26%21.73M | 686.41%22.97M | 54.40%17.61M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |